


Data Sheet

Product Name:	XY028-133
Cat. No.:	CS-0103866
CAS No.:	2229974-73-4
Molecular Formula:	C ₅₃ H ₆₇ N ₁₁ O ₇ S
Molecular Weight:	1002.23
Target:	CDK; PROTACs
Pathway:	Cell Cycle/DNA Damage; PROTAC
Solubility:	DMSO : 50 mg/mL (49.89 mM; Need ultrasonic)



BIOLOGICAL ACTIVITY:

XY028-133 (example 14) is a **PROTAC**-based **CDK4/6** degrader with anti-tumor activity, which consists of ligands for **von Hippel-Lindau** and **CDK**^[1]. *In Vitro*: XY028-133 (1 and 3 μM, 24 h) significantly decreases CDK4/6, Cyclin A, PLK1 and pRb protein levels in A375 cells^[1].

References:

[1]. JIN, Jian, et al. COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER. Patent. US2017/065027.

CAIndexNames:

L-Prolinamide, N-[7-[4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinyl]-1,7-dioxoheptyl]-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-, (4R)-

SMILES:

O=C(NCC1=CC=C(C2=C(C)N=CS2)C=C1)[C@H]3N(C([C@H](C(C)C)NC(CCCCCN4CCN(C5=CC=C(NC6=NC=C(C(C)=C(C(C)=O)C(N7C8CCCC8)=O)C7=N6)N=C5)CC4)=O)=O)C[C@H](O)C3

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA